ZUG, SWITZERLAND -- Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil.

Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region.

“Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well-positioned to bring this important therapy to patients living with autoimmune diseases. Together, we aim to improve access to effective and affordable treatment options across the region.”

“Our collaboration with Polpharma Biologics marks a significant milestone for Tuteur,” said Jonathan Hahn, President of Tuteur. “Partnering with an organization of their caliber reinforces our commitment to expanding access to world-class biologics for patients throughout Latin America.”

The biosimilar, currently in development, is designed to provide an effective and well-tolerated treatment option for patients with autoimmune conditions. Regulatory submission is anticipated within the next three years.